Boukovinas et al [14] reported the mRNA expression of BRCA1, RRM1 and RRM2 is potentially a useful tool for first-line gemcitabine plus docetaxel for NSCLC patients. This evidence concerns the gene BRCA1 and non-small cell lung carcinoma.